Zydus Lifesciences is currently trading at Rs. 507.55, up by 3.90 points or 0.77% from its previous closing of Rs. 503.65 on the BSE.
The scrip opened at Rs. 505.05 and has touched a high and low of Rs. 508.20 and Rs. 504.45 respectively. So far 2971 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 508.20 on 17-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 508.20 and Rs. 492.40 respectively. The current market cap of the company is Rs. 50979.66 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.02% and 8.00% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Isoproterenol Hydrochloride Injection USP, 0.2 mg/mL and 1 mg/5 mL (0.2 mg/mL) single-dose vials (USRLD: Isuprel Injection).
Isoproterenol hydrochloride injection is indicated to improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output and for treatment of bronchospasm occurring during anaesthesia. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India). Isoproterenol Hydrochloride Injection USP, 0.2 mg/mL and 1 mg/5 mL (0.2 mg/mL) had annual sales of $28.5 million in the United States (IQVIA MAT Feb. 2023).
The group now has 362 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.